DGX
Quest Diagnostics
September 21, 2026 · after-hours
- Rarity
- 3.88
- Peak move
- −9.73%
- Float cap
- $26.8B
Quest Diagnostics provides diagnostic information services through laboratory testing, offering insights from clinical lab results to help physicians, hospitals, patients, consumers, health plans, government agencies, employers, and other healthcare organizations improve health outcomes. It operates patient service centers, laboratory facilities, and consumer-initiated testing through QuestHealth.com. The company serves about half of U.S. physicians and hospitals annually.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
5 events · 0 from SEC or newswire · 0 timed with the move- Key event
executive_remarkQuest Diagnostics CEO Jim Davis said the company is outpacing its investor-day growth framework, with 2025 revenue up about 12% and 2026 guidance for nearly 8% revenue growth and over 13% EPS growth, a roughly $250 million consumer-testing business expected to grow at least 30%, and $2.8 billion deployed on M&A since 2024.
- Key event
analyst_ratingTruist Financial raised its price target on Quest Diagnostics to $260.00 from $250.00 on Sept 21, 2026, maintaining a Hold rating.
clinical_readoutQuest Diagnostics announced a study published in JAMA Network Open of over 193,000 patients finding that nearly 1 in 3 with suspected Lyme disease are co-positive for other tick-borne pathogens.
- Key event
financial_regulatoryCMS released preliminary CY2027 Clinical Laboratory Fee Schedule rates on Sept 21, 2026, phasing in Medicare lab reimbursement cuts of up to 15% annually from Jan 1, 2027 to address Medicare paying labs about 16% more than private payors, saving an estimated $1 billion annually.
reg_fd_disclosureQuest Diagnostics published a national survey of 1,024 registered voters on Sept 16, 2026 finding 88% would be concerned if Medicare lab payment rates were set too low and 74% want Congress to block PAMA cuts of up to 15% scheduled for Jan 1, 2027.